Ozempic and Wegovy May Reduce Risk of Multiple Diseases: Large-Scale Study
A study of 1.2 million veterans' health records suggests that Ozempic and Wegovy, GLP-1 receptor agonists, may reduce risks of schizophrenia, Alzheimer's, and substance abuse, although further research is needed due to the study's limitations.
Ozempic and Wegovy May Reduce Risk of Multiple Diseases: Large-Scale Study
A study of 1.2 million veterans' health records suggests that Ozempic and Wegovy, GLP-1 receptor agonists, may reduce risks of schizophrenia, Alzheimer's, and substance abuse, although further research is needed due to the study's limitations.
Progress
52% Bias Score
Fat Cell Memory Explains Weight Regain After Dieting
A Nature study reveals that fat cells 'remember' being fat, making weight loss difficult; 90% of dieters regain weight due to epigenetic changes in fat cells that persist even after weight loss, highlighting the need for long-term lifestyle changes for sustainable weight management.
Fat Cell Memory Explains Weight Regain After Dieting
A Nature study reveals that fat cells 'remember' being fat, making weight loss difficult; 90% of dieters regain weight due to epigenetic changes in fat cells that persist even after weight loss, highlighting the need for long-term lifestyle changes for sustainable weight management.
Progress
40% Bias Score
Soaring Demand for Expensive Weight-Loss Drugs in the Netherlands
The number of Dutch citizens purchasing costly new weight-loss drugs increased dramatically from 2000 prescriptions in 2022 to 109,000 in 2023, raising concerns about accessibility and the strain on the healthcare system due to high costs and potential exacerbation of health inequalities.
Soaring Demand for Expensive Weight-Loss Drugs in the Netherlands
The number of Dutch citizens purchasing costly new weight-loss drugs increased dramatically from 2000 prescriptions in 2022 to 109,000 in 2023, raising concerns about accessibility and the strain on the healthcare system due to high costs and potential exacerbation of health inequalities.
Progress
52% Bias Score
GLP-1RA Drugs Show Potential Link to Reduced Risk of Mental Health and Cognitive Conditions
A study of over 1.2 million veterans' medical records suggests a possible link between GLP-1 receptor agonist drugs, such as Ozempic and Wegovy, and a reduced risk of various mental health conditions, including suicidal thoughts, schizophrenia, dementia, and Alzheimer's disease, although further res...
GLP-1RA Drugs Show Potential Link to Reduced Risk of Mental Health and Cognitive Conditions
A study of over 1.2 million veterans' medical records suggests a possible link between GLP-1 receptor agonist drugs, such as Ozempic and Wegovy, and a reduced risk of various mental health conditions, including suicidal thoughts, schizophrenia, dementia, and Alzheimer's disease, although further res...
Progress
44% Bias Score
GLP-1 Drugs Show Unexpected Health Impacts in Large-Scale Study
A study of 215,970 diabetic patients using GLP-1 receptor antagonist drugs found lower risks of 42 conditions (including cardiovascular disease, bacterial infections, and Alzheimer's) and higher risks of 19 (including nausea, low blood pressure, and joint pain) compared to other treatments; further ...
GLP-1 Drugs Show Unexpected Health Impacts in Large-Scale Study
A study of 215,970 diabetic patients using GLP-1 receptor antagonist drugs found lower risks of 42 conditions (including cardiovascular disease, bacterial infections, and Alzheimer's) and higher risks of 19 (including nausea, low blood pressure, and joint pain) compared to other treatments; further ...
Progress
16% Bias Score
Weight-Loss Drugs Double Pancreatitis Risk: Major Study
A Washington University study of over 2 million diabetes patients found that weight-loss drugs like Ozempic doubled the risk of pancreatitis and increased risks of nausea/vomiting (30%), arthritis (11%), headaches (10%), and sleep disturbances (12%), despite also showing benefits in cardiovascular a...
Weight-Loss Drugs Double Pancreatitis Risk: Major Study
A Washington University study of over 2 million diabetes patients found that weight-loss drugs like Ozempic doubled the risk of pancreatitis and increased risks of nausea/vomiting (30%), arthritis (11%), headaches (10%), and sleep disturbances (12%), despite also showing benefits in cardiovascular a...
Progress
52% Bias Score
Ozempic and Surgery: Increased Aspiration Risk
The U.K.'s MHRA warns that weight-loss drugs like Ozempic increase the risk of aspiration (stomach contents entering the lungs) during surgery due to slow gastric emptying, reporting a small number of cases, one resulting in aspiration pneumonia; patients should inform their healthcare providers.
Ozempic and Surgery: Increased Aspiration Risk
The U.K.'s MHRA warns that weight-loss drugs like Ozempic increase the risk of aspiration (stomach contents entering the lungs) during surgery due to slow gastric emptying, reporting a small number of cases, one resulting in aspiration pneumonia; patients should inform their healthcare providers.
Progress
52% Bias Score
GLP-1 RA Drugs Show Promise, but Limitations Remain
A study of 1.2 million medical records found that GLP-1 RA drugs, such as Ozempic and Wegovy, may reduce the risk of several health issues, including substance use disorders, psychiatric disorders, and dementia, by 8-18%, but also carry risks of nausea, vomiting, and pancreatic or kidney complicatio...
GLP-1 RA Drugs Show Promise, but Limitations Remain
A study of 1.2 million medical records found that GLP-1 RA drugs, such as Ozempic and Wegovy, may reduce the risk of several health issues, including substance use disorders, psychiatric disorders, and dementia, by 8-18%, but also carry risks of nausea, vomiting, and pancreatic or kidney complicatio...
Progress
44% Bias Score
Diabetes Drugs Linked to Reduced Risk of Mental Health Issues
A study of 1.2 million veterans' medical records found that the diabetes and weight-loss drugs Ozempic and Wegovy (GLP-1 receptor agonists) may be linked to a reduced risk of various mental health issues, including alcohol and substance use disorders, suicidal thoughts, schizophrenia, dementia, and ...
Diabetes Drugs Linked to Reduced Risk of Mental Health Issues
A study of 1.2 million veterans' medical records found that the diabetes and weight-loss drugs Ozempic and Wegovy (GLP-1 receptor agonists) may be linked to a reduced risk of various mental health issues, including alcohol and substance use disorders, suicidal thoughts, schizophrenia, dementia, and ...
Progress
24% Bias Score
GLP-1 Drugs Show Significant Health Benefits and Risks in Large-Scale Study
A study of over two million veterans found that GLP-1 drugs, such as Ozempic, significantly reduce risks of neurocognitive disorders, addiction, and self-harm, but also increase the risk of pancreatic and kidney problems.
GLP-1 Drugs Show Significant Health Benefits and Risks in Large-Scale Study
A study of over two million veterans found that GLP-1 drugs, such as Ozempic, significantly reduce risks of neurocognitive disorders, addiction, and self-harm, but also increase the risk of pancreatic and kidney problems.
Progress
52% Bias Score
GLP-1 Weight-Loss Drugs: Significant Health Benefits and Risks Revealed
A study of over 2.4 million people found that GLP-1 weight-loss medications reduced the risk of 42 health conditions, including cardiac arrest and Alzheimer's disease, by reducing inflammation and improving impulse control, but increased risks of gastrointestinal issues were also observed.
GLP-1 Weight-Loss Drugs: Significant Health Benefits and Risks Revealed
A study of over 2.4 million people found that GLP-1 weight-loss medications reduced the risk of 42 health conditions, including cardiac arrest and Alzheimer's disease, by reducing inflammation and improving impulse control, but increased risks of gastrointestinal issues were also observed.
Progress
36% Bias Score
Medicare to Negotiate Prices for Ozempic, Wegovy, and 13 Other Drugs
Medicare will negotiate prices for Ozempic, Wegovy, and 13 other drugs, impacting 5.3 million Part D users and $41 billion in drug costs, with negotiated prices effective in 2027.
Medicare to Negotiate Prices for Ozempic, Wegovy, and 13 Other Drugs
Medicare will negotiate prices for Ozempic, Wegovy, and 13 other drugs, impacting 5.3 million Part D users and $41 billion in drug costs, with negotiated prices effective in 2027.
Progress
32% Bias Score